BMG Labtech GmbH

What does BMG Labtech own?

The company owns the BMG LABTECH brand, its Ortenberg manufacturing and headquarters site, five international subsidiaries in the US, UK, France, Japan, and Australia, and the BioDataAnalysis software capability merged into the business in 2024.

Is BMG Labtech publicly traded?

No. BMG Labtech GmbH is a private family-owned company. It has no shares listed on any exchange, no venture capital investors, and no corporate parent.

Who founded BMG Labtech?

Dr. Bela Gurath, a physicist, founded the company in Offenburg, Germany, in 1989. Thomas Rabiger joined as a shareholder in the early years and now leads the company as owner and managing director.

Where is BMG Labtech headquartered?

The company is headquartered at Allmendgrün 8 in Ortenberg, Baden-Wurttemberg, Germany, in the Ortenau district near Offenburg. All instruments are designed, assembled, and tested at this site.

How many brands does BMG Labtech own?

One. BMG LABTECH is the company's only brand, covering all of its microplate reader platforms, software, accessories, and services.

Who owns BMG Labtech?

The company is family-owned. Thomas Rabiger is the principal shareholder and managing director. There are no institutional investors or external shareholders.

What are BMG Labtech's main products?

Its product line is microplate readers: the FLUOstar, PHERAstar, CLARIOstar, SPECTROstar, VANTAstar, and Omega series, covering detection modes from absorbance and luminescence to time-resolved fluorescence and Alpha technology, plus software and accessories.

Dr. Bela Gurath, a physicist, founded the company in Offenburg in 1989 as a one-man engineering office. The first years were spent designing microplate reading and handling components for other manufacturers while the team determined its strategy. Thomas Rabiger joined as a shareholder during this period.

The decision to build complete instruments came in 1993, when a development grant funded a fluorescence measurement device. The result was the FLUOstar, the second fluorescence-based microplate reader on the market. It launched the company on the path it has followed for three decades: dedicated and multi-mode readers for research applications.

The product family expanded through the 1990s and 2000s. The LUMIstar, NEPHELOstar, and SPECTROstar covered luminescence, nephelometry, and absorbance. The PHERAstar targeted high-throughput screening in drug discovery. The CLARIOstar became the flagship multi-mode platform, adding atmospheric control and monochromator flexibility. The VANTAstar and Omega series completed the lineup.

The headquarters moved to purpose-built premises in Ortenberg and later expanded as growth continued. International subsidiaries opened in the United States, United Kingdom, France, Japan, and Australia. In January 2024 the company acquired additional shares in BioDataAnalysis GmbH and merged it into the business, bringing assay software and data analysis in-house. Through 2026 the company remains independent, owner-managed, and focused on a single product category.

As a small manufacturer, the company's sustainability posture is modest and practical. Single-site German production keeps its manufacturing footprint concentrated and subject to EU environmental regulation, and the durability of its instruments supports a long product life rather than disposable hardware.

No independent certifications such as B Corp apply, and the company does not publish a standalone ESG report. Its strongest environmental characteristic is inherent to its model: premium instruments designed for decades of lab service, manufactured at one regulated European site.